25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Biotest Aktiengesellschaft
Buy, Hold or Sell?

Let's analyze Biotest together

I guess you are interested in Biotest Aktiengesellschaft. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Biotest Aktiengesellschaft. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Biotest Aktiengesellschaft

I send you an email if I find something interesting about Biotest Aktiengesellschaft.

1. Quick Overview

1.1. Quick analysis of Biotest (30 sec.)










1.2. What can you expect buying and holding a share of Biotest? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
57.5%

What is your share worth?

Current worth
€13.54
Expected worth in 1 year
€17.65
How sure are you?
47.5%

+ What do you gain per year?

Total Gains per Share
€4.10
Return On Investment
15.1%

For what price can you sell your share?

Current Price per Share
€27.20
Expected price per share
€23.57 - €27.60
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Biotest (5 min.)




Live pricePrice per Share (EOD)
€27.20
Intrinsic Value Per Share
€27.59 - €77.01
Total Value Per Share
€41.13 - €90.56

2.2. Growth of Biotest (5 min.)




Is Biotest growing?

Current yearPrevious yearGrowGrow %
How rich?$593.7m$398.7m$161.5m28.8%

How much money is Biotest making?

Current yearPrevious yearGrowGrow %
Making money$53.2m-$2.7m$56m105.2%
Net Profit Margin21.5%-3.8%--

How much money comes from the company's main activities?

2.3. Financial Health of Biotest (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#98 / 967

Most Revenue
#46 / 967

Most Profit
#29 / 967
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Biotest?

Welcome investor! Biotest's management wants to use your money to grow the business. In return you get a share of Biotest.

First you should know what it really means to hold a share of Biotest. And how you can make/lose money.

Speculation

The Price per Share of Biotest is €27.20. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Biotest.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Biotest, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €13.54. Based on the TTM, the Book Value Change Per Share is €1.03 per quarter. Based on the YOY, the Book Value Change Per Share is €0.03 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Biotest.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.271.0%1.354.9%0.361.3%0.130.5%0.120.4%
Usd Book Value Change Per Share0.220.8%1.144.2%0.030.1%0.150.5%0.050.2%
Usd Dividend Per Share0.000.0%0.000.0%0.010.0%0.010.0%0.020.1%
Usd Total Gains Per Share0.220.8%1.144.2%0.040.1%0.160.6%0.070.3%
Usd Price Per Share29.58-32.21-36.42-32.97-34.78-
Price to Earnings Ratio27.23-11.73-5.06--20.05--228.16-
Price-to-Total Gains Ratio132.07-53.66--4.67--25.90--19.76-
Price to Book Ratio1.97-2.29-3.60-2.73-2.84-
Price-to-Total Gains Ratio132.07-53.66--4.67--25.90--19.76-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share30.13488
Number of shares33
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.01
Usd Book Value Change Per Share1.140.15
Usd Total Gains Per Share1.140.16
Gains per Quarter (33 shares)37.515.32
Gains per Year (33 shares)150.0421.26
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1015014022011
2030029033932
3045044055953
4060059067974
5075074089895
6090089010118116
701050104011138137
801200119013157158
901350134014177179
1001500149016197200

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%7.05.00.058.3%7.013.00.035.0%18.022.00.045.0%40.022.00.064.5%
Book Value Change Per Share4.00.00.0100.0%7.05.00.058.3%10.010.00.050.0%19.021.00.047.5%34.025.03.054.8%
Dividend per Share0.00.04.00.0%3.00.09.025.0%10.00.010.050.0%23.00.017.057.5%25.00.037.040.3%
Total Gains per Share4.00.00.0100.0%7.05.00.058.3%10.010.00.050.0%19.021.00.047.5%34.025.03.054.8%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Biotest Aktiengesellschaft compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.2021.026-80%0.028+619%0.134+50%0.042+386%
Book Value Per Share--13.54312.778+6%9.146+48%11.278+20%11.082+22%
Current Ratio--2.4532.863-14%4.741-48%4.430-45%4.027-39%
Debt To Asset Ratio--0.6100.640-5%0.693-12%0.636-4%0.607+1%
Debt To Equity Ratio--1.5671.784-12%2.255-31%1.786-12%1.595-2%
Dividend Per Share----0%0.005-100%0.011-100%0.021-100%
Eps--0.2451.214-80%0.328-25%0.121+102%0.108+127%
Free Cash Flow Per Share--1.4760.547+170%-0.928+163%-0.186+113%-0.228+115%
Free Cash Flow To Equity Per Share---0.3510.051-786%-0.342-3%-0.030-91%-0.148-58%
Gross Profit Margin---0.3510.435-181%-0.310-11%-0.072-79%4.700-107%
Intrinsic Value_10Y_max--77.012--------
Intrinsic Value_10Y_min--27.587--------
Intrinsic Value_1Y_max--0.931--------
Intrinsic Value_1Y_min---0.289--------
Intrinsic Value_3Y_max--7.970--------
Intrinsic Value_3Y_min--1.771--------
Intrinsic Value_5Y_max--21.243--------
Intrinsic Value_5Y_min--6.708--------
Market Cap538171040.000-96%1056557768.4001150539966.900-8%1293021518.850-18%1137035991.330-7%1221500649.323-14%
Net Profit Margin--0.0620.215-71%-0.038+161%-0.014+122%1.562-96%
Operating Margin--0.1260.218-42%-0.035+128%-0.026+120%0.494-75%
Operating Ratio--0.9010.748+20%0.989-9%0.973-7%2.454-63%
Pb Ratio2.008+2%1.9722.294-14%3.598-45%2.730-28%2.836-30%
Pe Ratio27.741+2%27.23111.728+132%5.063+438%-20.052+174%-228.164+938%
Price Per Share27.200+2%26.70029.075-8%32.875-19%29.760-10%31.396-15%
Price To Free Cash Flow Ratio4.608+2%4.52311.232-60%-10.190+325%2.285+98%-17.518+487%
Price To Total Gains Ratio134.543+2%132.07053.664+146%-4.667+104%-25.905+120%-19.759+115%
Quick Ratio--0.8491.233-31%2.261-62%2.133-60%2.186-61%
Return On Assets--0.0070.035-80%-0.003+136%0.001+599%0.001+858%
Return On Equity--0.0180.100-82%-0.008+146%0.003+420%0.003+459%
Total Gains Per Share--0.2021.026-80%0.033+510%0.145+39%0.063+222%
Usd Book Value--593723610.000560209635.000+6%398705512.500+49%477421807.500+24%475336185.750+25%
Usd Book Value Change Per Share--0.2241.137-80%0.031+619%0.149+50%0.046+386%
Usd Book Value Per Share--15.00414.157+6%10.133+48%12.495+20%12.277+22%
Usd Dividend Per Share----0%0.006-100%0.012-100%0.024-100%
Usd Eps--0.2721.345-80%0.364-25%0.134+102%0.120+127%
Usd Free Cash Flow--64701360.00023986035.000+170%-40576837.500+163%-8059972.500+112%-10065271.472+116%
Usd Free Cash Flow Per Share--1.6350.606+170%-1.029+163%-0.206+113%-0.253+115%
Usd Free Cash Flow To Equity Per Share---0.3890.057-786%-0.379-3%-0.034-91%-0.164-58%
Usd Market Cap596239695.216-96%1170560351.6101274683229.329-8%1432538540.734-18%1259722174.795-7%1353300569.385-14%
Usd Price Per Share30.135+2%29.58132.212-8%36.422-19%32.971-10%34.784-15%
Usd Profit--10746630.00053234595.000-80%-2769750.000+126%3373555.500+219%3298772.250+226%
Usd Revenue--173718720.000224100472.500-22%149067945.000+17%156446559.000+11%145644534.000+19%
Usd Total Gains Per Share--0.2241.137-80%0.037+510%0.161+39%0.070+222%
 EOD+2 -6MRQTTM+12 -22YOY+22 -145Y+24 -1210Y+21 -15

3.3 Fundamental Score

Let's check the fundamental score of Biotest Aktiengesellschaft based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1527.741
Price to Book Ratio (EOD)Between0-12.008
Net Profit Margin (MRQ)Greater than00.062
Operating Margin (MRQ)Greater than00.126
Quick Ratio (MRQ)Greater than10.849
Current Ratio (MRQ)Greater than12.453
Debt to Asset Ratio (MRQ)Less than10.610
Debt to Equity Ratio (MRQ)Less than11.567
Return on Equity (MRQ)Greater than0.150.018
Return on Assets (MRQ)Greater than0.050.007
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Biotest Aktiengesellschaft based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5058.278
Ma 20Greater thanMa 5026.335
Ma 50Greater thanMa 10026.836
Ma 100Greater thanMa 20027.075
OpenGreater thanClose27.000
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Biotest Aktiengesellschaft

Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through three segments: European Union, Rest of the World, and Stateless. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infection; Fovepta for immunoprophylaxis of hepatitis B in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and Yimmugo for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, including neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B immunoglobulins. In addition, it provides Albiomin and Biseco to restore and maintain circulating blood volume; Cofact for deficiency of coagulation factors; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft is a subsidiary of Grifols, S.A.

Fundamental data was last updated by Penke on 2024-09-10 15:48:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating efficient.
The company is efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is underpriced.
Based on how much money comes from the company's main activities, the company is cheap.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Biotest earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Biotest to the Biotechnology industry mean.
  • A Net Profit Margin of 6.2% means that €0.06 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Biotest Aktiengesellschaft:

  • The MRQ is 6.2%. The company is making a profit. +1
  • The TTM is 21.5%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ6.2%TTM21.5%-15.3%
TTM21.5%YOY-3.8%+25.3%
TTM21.5%5Y-1.4%+22.9%
5Y-1.4%10Y156.2%-157.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.2%-133.6%+139.8%
TTM21.5%-212.2%+233.7%
YOY-3.8%-228.3%+224.5%
5Y-1.4%-375.5%+374.1%
10Y156.2%-493.9%+650.1%
4.3.1.2. Return on Assets

Shows how efficient Biotest is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Biotest to the Biotechnology industry mean.
  • 0.7% Return on Assets means that Biotest generated €0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Biotest Aktiengesellschaft:

  • The MRQ is 0.7%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 3.5%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ0.7%TTM3.5%-2.8%
TTM3.5%YOY-0.3%+3.7%
TTM3.5%5Y0.1%+3.4%
5Y0.1%10Y0.1%+0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7%-11.0%+11.7%
TTM3.5%-11.7%+15.2%
YOY-0.3%-11.2%+10.9%
5Y0.1%-12.9%+13.0%
10Y0.1%-14.4%+14.5%
4.3.1.3. Return on Equity

Shows how efficient Biotest is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Biotest to the Biotechnology industry mean.
  • 1.8% Return on Equity means Biotest generated €0.02 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Biotest Aktiengesellschaft:

  • The MRQ is 1.8%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 10.0%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ1.8%TTM10.0%-8.2%
TTM10.0%YOY-0.8%+10.8%
TTM10.0%5Y0.3%+9.7%
5Y0.3%10Y0.3%+0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8%-13.5%+15.3%
TTM10.0%-16.1%+26.1%
YOY-0.8%-13.6%+12.8%
5Y0.3%-18.9%+19.2%
10Y0.3%-19.1%+19.4%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Biotest Aktiengesellschaft.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Biotest is operating .

  • Measures how much profit Biotest makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Biotest to the Biotechnology industry mean.
  • An Operating Margin of 12.6% means the company generated €0.13  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Biotest Aktiengesellschaft:

  • The MRQ is 12.6%. The company is operating less efficient.
  • The TTM is 21.8%. The company is operating efficient. +1
Trends
Current periodCompared to+/- 
MRQ12.6%TTM21.8%-9.3%
TTM21.8%YOY-3.5%+25.3%
TTM21.8%5Y-2.6%+24.4%
5Y-2.6%10Y49.4%-52.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ12.6%-277.8%+290.4%
TTM21.8%-273.4%+295.2%
YOY-3.5%-235.6%+232.1%
5Y-2.6%-386.0%+383.4%
10Y49.4%-497.6%+547.0%
4.3.2.2. Operating Ratio

Measures how efficient Biotest is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.90 means that the operating costs are €0.90 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Biotest Aktiengesellschaft:

  • The MRQ is 0.901. The company is less efficient in keeping operating costs low.
  • The TTM is 0.748. The company is efficient in keeping operating costs low. +1
Trends
Current periodCompared to+/- 
MRQ0.901TTM0.748+0.153
TTM0.748YOY0.989-0.241
TTM0.7485Y0.973-0.225
5Y0.97310Y2.454-1.481
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9012.768-1.867
TTM0.7483.251-2.503
YOY0.9893.438-2.449
5Y0.9735.096-4.123
10Y2.4546.572-4.118
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Biotest Aktiengesellschaft.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Biotest is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.45 means the company has €2.45 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Biotest Aktiengesellschaft:

  • The MRQ is 2.453. The company is able to pay all its short-term debts. +1
  • The TTM is 2.863. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.453TTM2.863-0.410
TTM2.863YOY4.741-1.878
TTM2.8635Y4.430-1.567
5Y4.43010Y4.027+0.403
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.4533.736-1.283
TTM2.8633.909-1.046
YOY4.7414.740+0.001
5Y4.4305.946-1.516
10Y4.0276.296-2.269
4.4.3.2. Quick Ratio

Measures if Biotest is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Biotest to the Biotechnology industry mean.
  • A Quick Ratio of 0.85 means the company can pay off €0.85 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Biotest Aktiengesellschaft:

  • The MRQ is 0.849. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 1.233. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ0.849TTM1.233-0.384
TTM1.233YOY2.261-1.028
TTM1.2335Y2.133-0.900
5Y2.13310Y2.186-0.053
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8492.773-1.924
TTM1.2333.342-2.109
YOY2.2614.693-2.432
5Y2.1335.859-3.726
10Y2.1866.460-4.274
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Biotest Aktiengesellschaft.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Biotest assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Biotest to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.61 means that Biotest assets are financed with 61.0% credit (debt) and the remaining percentage (100% - 61.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Biotest Aktiengesellschaft:

  • The MRQ is 0.610. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.640. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.610TTM0.640-0.029
TTM0.640YOY0.693-0.053
TTM0.6405Y0.636+0.004
5Y0.63610Y0.607+0.029
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6100.341+0.269
TTM0.6400.346+0.294
YOY0.6930.306+0.387
5Y0.6360.365+0.271
10Y0.6070.382+0.225
4.5.4.2. Debt to Equity Ratio

Measures if Biotest is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Biotest to the Biotechnology industry mean.
  • A Debt to Equity ratio of 156.7% means that company has €1.57 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Biotest Aktiengesellschaft:

  • The MRQ is 1.567. The company is just able to pay all its debts with equity.
  • The TTM is 1.784. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ1.567TTM1.784-0.217
TTM1.784YOY2.255-0.471
TTM1.7845Y1.786-0.001
5Y1.78610Y1.595+0.191
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5670.396+1.171
TTM1.7840.449+1.335
YOY2.2550.372+1.883
5Y1.7860.450+1.336
10Y1.5950.488+1.107
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Biotest generates.

  • Above 15 is considered overpriced but always compare Biotest to the Biotechnology industry mean.
  • A PE ratio of 27.23 means the investor is paying €27.23 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Biotest Aktiengesellschaft:

  • The EOD is 27.741. Based on the earnings, the company is overpriced. -1
  • The MRQ is 27.231. Based on the earnings, the company is overpriced. -1
  • The TTM is 11.728. Based on the earnings, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD27.741MRQ27.231+0.510
MRQ27.231TTM11.728+15.503
TTM11.728YOY5.063+6.666
TTM11.7285Y-20.052+31.780
5Y-20.05210Y-228.164+208.113
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD27.741-2.294+30.035
MRQ27.231-2.445+29.676
TTM11.728-2.977+14.705
YOY5.063-3.465+8.528
5Y-20.052-6.081-13.971
10Y-228.164-6.202-221.962
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Biotest Aktiengesellschaft:

  • The EOD is 4.608. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 4.523. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 11.232. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD4.608MRQ4.523+0.085
MRQ4.523TTM11.232-6.709
TTM11.232YOY-10.190+21.422
TTM11.2325Y2.285+8.947
5Y2.28510Y-17.518+19.802
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.608-3.047+7.655
MRQ4.523-3.282+7.805
TTM11.232-3.604+14.836
YOY-10.190-4.753-5.437
5Y2.285-8.064+10.349
10Y-17.518-8.612-8.906
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Biotest is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.97 means the investor is paying €1.97 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Biotest Aktiengesellschaft:

  • The EOD is 2.008. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.972. Based on the equity, the company is underpriced. +1
  • The TTM is 2.294. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.008MRQ1.972+0.037
MRQ1.972TTM2.294-0.322
TTM2.294YOY3.598-1.304
TTM2.2945Y2.730-0.436
5Y2.73010Y2.836-0.105
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.0081.826+0.182
MRQ1.9721.903+0.069
TTM2.2942.239+0.055
YOY3.5982.399+1.199
5Y2.7303.551-0.821
10Y2.8364.109-1.273
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-06-302023-09-302023-12-312024-03-312024-06-30
Total Other Income Expense Net -9,300-1,400-10,700-4,600-15,3005,000-10,30012,1001,800



6.2. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in EUR. All numbers in thousands.

Summary
Total Assets1,375,800
Total Liabilities839,900
Total Stockholder Equity535,900
 As reported
Total Liabilities 839,900
Total Stockholder Equity+ 535,900
Total Assets = 1,375,800

Assets

Total Assets1,375,800
Total Current Assets738,900
Long-term Assets636,900
Total Current Assets
Cash And Cash Equivalents 66,300
Short-term Investments 18,400
Net Receivables 171,000
Inventory 472,500
Total Current Assets  (as reported)738,900
Total Current Assets  (calculated)728,200
+/- 10,700
Long-term Assets
Property Plant Equipment 575,400
Intangible Assets 15,000
Long-term Assets Other 100
Long-term Assets  (as reported)636,900
Long-term Assets  (calculated)590,500
+/- 46,400

Liabilities & Shareholders' Equity

Total Current Liabilities301,200
Long-term Liabilities538,700
Total Stockholder Equity535,900
Total Current Liabilities
Short-term Debt 194,600
Accounts payable 69,400
Other Current Liabilities 34,800
Total Current Liabilities  (as reported)301,200
Total Current Liabilities  (calculated)298,800
+/- 2,400
Long-term Liabilities
Long-term Liabilities  (as reported)538,700
Long-term Liabilities  (calculated)0
+/- 538,700
Total Stockholder Equity
Common Stock39,600
Retained Earnings 287,400
Accumulated Other Comprehensive Income -10,900
Other Stockholders Equity 219,800
Total Stockholder Equity (as reported)535,900
Total Stockholder Equity (calculated)535,900
+/-0
Other
Capital Stock39,600
Cash and Short Term Investments 66,300
Common Stock Shares Outstanding 39,571
Current Deferred Revenue2,400
Liabilities and Stockholders Equity 1,375,800
Net Debt 558,000
Net Invested Capital 535,900
Net Working Capital 437,700
Property Plant and Equipment Gross 575,400
Short Long Term Debt Total 624,300



6.3. Balance Sheets Structured

Currency in EUR. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-31
> Total Assets 
0
0
0
633,454
636,900
656,100
640,500
632,339
637,900
680,800
721,900
682,762
689,500
688,200
672,800
682,347
663,800
745,800
746,500
886,500
902,500
914,300
932,100
1,032,600
1,072,200
1,052,200
962,800
962,700
968,300
981,900
962,400
932,800
889,200
967,100
953,600
978,500
1,017,200
1,334,900
1,047,500
1,042,300
1,044,600
1,058,200
1,091,000
1,108,400
1,107,600
1,145,200
1,122,200
1,131,300
1,134,800
1,145,800
1,135,400
1,104,200
1,109,800
1,101,900
1,079,300
1,203,000
1,190,200
1,214,100
1,349,500
1,444,300
1,446,800
1,375,800
1,375,8001,446,8001,444,3001,349,5001,214,1001,190,2001,203,0001,079,3001,101,9001,109,8001,104,2001,135,4001,145,8001,134,8001,131,3001,122,2001,145,2001,107,6001,108,4001,091,0001,058,2001,044,6001,042,3001,047,5001,334,9001,017,200978,500953,600967,100889,200932,800962,400981,900968,300962,700962,8001,052,2001,072,2001,032,600932,100914,300902,500886,500746,500745,800663,800682,347672,800688,200689,500682,762721,900680,800637,900632,339640,500656,100636,900633,454000
   > Total Current Assets 
0
0
0
325,261
326,300
333,200
309,800
308,944
324,800
372,100
412,400
369,950
385,600
374,100
360,100
367,461
346,900
430,400
425,900
562,500
559,700
584,700
594,500
679,300
697,300
649,500
595,300
586,800
565,600
554,100
503,300
467,200
392,000
396,500
368,800
449,700
487,600
793,600
500,300
495,100
476,100
488,600
508,500
522,800
525,600
563,900
542,200
556,300
560,600
570,500
556,600
522,200
523,900
522,000
497,500
619,400
597,400
620,700
736,200
756,500
796,200
738,900
738,900796,200756,500736,200620,700597,400619,400497,500522,000523,900522,200556,600570,500560,600556,300542,200563,900525,600522,800508,500488,600476,100495,100500,300793,600487,600449,700368,800396,500392,000467,200503,300554,100565,600586,800595,300649,500697,300679,300594,500584,700559,700562,500425,900430,400346,900367,461360,100374,100385,600369,950412,400372,100324,800308,944309,800333,200326,300325,261000
       Cash And Cash Equivalents 
0
0
0
6,730
12,200
6,800
9,500
18,541
7,300
6,100
120,000
83,199
70,100
58,900
55,500
57,241
32,300
97,300
70,700
204,400
174,200
89,800
79,500
179,400
125,000
96,800
88,300
53,800
120,500
114,400
88,200
72,900
38,100
62,800
30,900
22,300
42,700
165,700
119,600
61,900
43,400
49,800
65,500
60,800
44,000
63,700
40,200
71,300
55,000
72,000
79,200
104,400
115,300
85,000
53,300
116,600
68,000
58,300
65,400
118,500
84,700
66,300
66,30084,700118,50065,40058,30068,000116,60053,30085,000115,300104,40079,20072,00055,00071,30040,20063,70044,00060,80065,50049,80043,40061,900119,600165,70042,70022,30030,90062,80038,10072,90088,200114,400120,50053,80088,30096,800125,000179,40079,50089,800174,200204,40070,70097,30032,30057,24155,50058,90070,10083,199120,0006,1007,30018,5419,5006,80012,2006,730000
       Short-term Investments 
0
0
0
0
-16,900
0
-2,300
0
0
0
0
0
0
0
0
-72
0
0
0
0
0
0
0
54,700
0
0
0
99,900
50,500
51,800
41,800
10,000
10,800
1,600
1,100
5,900
128,900
295,300
36,800
44,200
52,500
31,900
34,100
24,900
20,600
31,000
32,800
17,900
13,300
13,100
12,100
13,100
14,800
18,100
23,600
20,000
18,900
12,600
13,400
200
14,100
18,400
18,40014,10020013,40012,60018,90020,00023,60018,10014,80013,10012,10013,10013,30017,90032,80031,00020,60024,90034,10031,90052,50044,20036,800295,300128,9005,9001,1001,60010,80010,00041,80051,80050,50099,90000054,7000000000-7200000000-2,3000-16,9000000
       Net Receivables 
0
0
0
99,678
125,300
135,000
117,000
100,736
158,300
208,800
121,600
124,454
136,500
129,400
121,400
125,412
111,500
115,200
123,900
129,400
126,500
156,600
177,400
196,100
198,900
175,700
165,100
212,100
173,300
173,400
170,900
212,100
162,400
148,200
153,200
273,300
139,900
155,800
150,300
180,300
131,300
149,800
144,700
155,600
139,000
156,500
152,600
175,800
171,800
168,900
155,100
157,000
120,000
140,300
128,300
185,900
162,500
193,400
254,500
206,800
246,500
171,000
171,000246,500206,800254,500193,400162,500185,900128,300140,300120,000157,000155,100168,900171,800175,800152,600156,500139,000155,600144,700149,800131,300180,300150,300155,800139,900273,300153,200148,200162,400212,100170,900173,400173,300212,100165,100175,700198,900196,100177,400156,600126,500129,400123,900115,200111,500125,412121,400129,400136,500124,454121,600208,800158,300100,736117,000135,000125,30099,678000
       Other Current Assets 
0
0
0
48,527
20,800
21,000
15,400
40,956
14,100
11,400
10,600
9,314
11,300
8,100
5,700
592
9,100
7,100
8,300
1,700
12,000
74,600
70,100
3,100
121,800
133,400
115,800
2,300
13,000
11,300
15,600
1,400
13,500
13,200
13,700
1,300
11,000
10,800
14,000
400
12,900
10,100
6,900
1,400
9,600
8,400
9,700
1,200
18,700
13,400
12,100
3,100
18,000
15,400
23,600
3,100
20,400
15,300
29,300
11,900
26,300
29,100
29,10026,30011,90029,30015,30020,4003,10023,60015,40018,0003,10012,10013,40018,7001,2009,7008,4009,6001,4006,90010,10012,90040014,00010,80011,0001,30013,70013,20013,5001,40015,60011,30013,0002,300115,800133,400121,8003,10070,10074,60012,0001,7008,3007,1009,1005925,7008,10011,3009,31410,60011,40014,10040,95615,40021,00020,80048,527000
   > Long-term Assets 
0
0
0
308,193
310,600
322,900
330,700
323,395
313,100
308,700
309,500
312,812
303,900
314,100
312,700
314,886
316,900
315,400
320,600
324,000
342,800
329,600
337,600
353,300
374,900
402,700
367,500
375,900
402,700
427,800
459,100
465,600
497,200
570,600
584,800
528,800
529,600
541,300
547,200
547,200
568,500
569,600
582,500
585,600
582,000
581,300
580,000
575,000
574,200
575,300
578,800
582,000
585,900
579,900
581,800
583,600
592,700
593,400
613,300
687,800
650,600
636,900
636,900650,600687,800613,300593,400592,700583,600581,800579,900585,900582,000578,800575,300574,200575,000580,000581,300582,000585,600582,500569,600568,500547,200547,200541,300529,600528,800584,800570,600497,200465,600459,100427,800402,700375,900367,500402,700374,900353,300337,600329,600342,800324,000320,600315,400316,900314,886312,700314,100303,900312,812309,500308,700313,100323,395330,700322,900310,600308,193000
       Property Plant Equipment 
0
0
0
231,955
217,500
226,800
235,800
230,749
224,300
222,600
226,200
234,857
232,400
241,600
240,100
244,576
244,900
244,300
249,400
254,900
254,500
257,100
266,200
282,300
297,300
307,200
282,300
317,200
341,000
367,800
397,900
414,900
436,700
455,700
475,500
477,100
487,900
500,700
507,100
512,700
533,100
531,600
541,800
547,900
545,000
546,100
546,000
548,200
547,200
546,600
547,400
550,000
547,800
544,600
543,800
547,800
549,600
555,700
573,400
578,400
581,100
575,400
575,400581,100578,400573,400555,700549,600547,800543,800544,600547,800550,000547,400546,600547,200548,200546,000546,100545,000547,900541,800531,600533,100512,700507,100500,700487,900477,100475,500455,700436,700414,900397,900367,800341,000317,200282,300307,200297,300282,300266,200257,100254,500254,900249,400244,300244,900244,576240,100241,600232,400234,857226,200222,600224,300230,749235,800226,800217,500231,955000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
30,137
0
0
0
28,800
0
0
0
32,700
0
0
0
36,500
0
0
0
16,800
0
0
0
7,300
0
0
0
7,200
0
0
0
7,200
0
0
0
7,100
0
0
0
7,100
0
0
0
7,200
0
0
0
6,000
0
0
006,0000007,2000007,1000007,1000007,2000007,2000007,30000016,80000036,50000032,70000028,80000030,137000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,300
5,800
55,500
47,100
2,300
2,700
2,500
2,500
1,900
9,600
12,500
11,900
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000011,90012,5009,6001,9002,5002,5002,7002,30047,10055,5005,8004,3000000000000000000000000000000000
       Intangible Assets 
0
0
0
66,680
68,700
72,100
64,700
64,941
64,000
62,200
63,400
62,833
59,600
60,600
58,300
22,918
54,400
53,100
50,100
19,300
47,100
46,400
48,700
17,500
55,900
54,100
43,500
8,200
42,800
43,700
43,900
8,500
24,800
24,100
24,300
9,300
16,200
16,200
16,400
9,200
17,000
16,800
13,900
6,600
13,700
13,700
13,500
6,900
13,700
13,500
13,500
4,100
11,400
11,700
11,900
9,200
20,700
15,500
15,800
9,000
15,000
15,000
15,00015,0009,00015,80015,50020,7009,20011,90011,70011,4004,10013,50013,50013,7006,90013,50013,70013,7006,60013,90016,80017,0009,20016,40016,20016,2009,30024,30024,10024,8008,50043,90043,70042,8008,20043,50054,10055,90017,50048,70046,40047,10019,30050,10053,10054,40022,91858,30060,60059,60062,83363,40062,20064,00064,94164,70072,10068,70066,680000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
243,900
29,900
35,300
37,900
216,500
22,800
21,900
21,200
227,200
8,800
8,700
14,900
251,600
13,600
12,000
11,400
249,700
10,700
12,600
15,300
90,400
22,200
19,700
21,300
0
100
17,100
0
0
0
0
000017,100100021,30019,70022,20090,40015,30012,60010,700249,70011,40012,00013,600251,60014,9008,7008,800227,20021,20021,90022,800216,50037,90035,30029,900243,9000000000000000000000000000000000
> Total Liabilities 
0
0
0
363,592
339,200
347,600
339,800
324,731
329,300
372,900
382,100
336,094
341,400
334,300
315,400
312,914
285,200
293,000
290,200
425,800
436,800
446,200
445,300
552,400
569,300
568,200
564,600
550,400
558,200
565,200
555,400
572,100
553,300
627,600
622,200
630,700
677,100
835,900
542,200
547,100
550,700
562,000
599,300
631,500
641,400
685,900
678,000
689,700
707,100
723,400
723,200
723,800
734,700
743,200
735,500
831,900
839,100
840,600
889,600
945,400
918,900
839,900
839,900918,900945,400889,600840,600839,100831,900735,500743,200734,700723,800723,200723,400707,100689,700678,000685,900641,400631,500599,300562,000550,700547,100542,200835,900677,100630,700622,200627,600553,300572,100555,400565,200558,200550,400564,600568,200569,300552,400445,300446,200436,800425,800290,200293,000285,200312,914315,400334,300341,400336,094382,100372,900329,300324,731339,800347,600339,200363,592000
   > Total Current Liabilities 
0
0
0
148,777
119,700
122,200
120,700
131,348
140,300
153,000
162,700
147,735
159,700
153,100
141,400
164,877
137,800
148,200
147,500
124,300
121,000
131,100
129,700
128,900
132,500
131,000
129,500
125,800
125,200
135,600
128,200
146,000
118,500
135,100
136,500
251,200
385,000
381,400
131,100
125,600
107,800
415,600
101,100
115,000
123,100
113,800
103,300
105,600
121,100
111,100
103,800
106,400
114,900
122,200
109,600
130,200
129,500
122,800
147,200
385,300
391,200
301,200
301,200391,200385,300147,200122,800129,500130,200109,600122,200114,900106,400103,800111,100121,100105,600103,300113,800123,100115,000101,100415,600107,800125,600131,100381,400385,000251,200136,500135,100118,500146,000128,200135,600125,200125,800129,500131,000132,500128,900129,700131,100121,000124,300147,500148,200137,800164,877141,400153,100159,700147,735162,700153,000140,300131,348120,700122,200119,700148,777000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
41,445
32,400
32,500
29,900
5,300
5,400
5,600
7,300
6,100
7,700
10,100
10,800
9,100
9,700
15,000
17,200
16,200
17,200
17,900
23,900
119,600
269,900
254,800
34,300
700
2,400
302,500
6,900
7,300
5,900
8,100
7,800
7,900
8,500
9,000
8,800
6,400
35,900
39,700
42,100
9,400
32,000
33,600
43,800
260,100
263,700
194,600
194,600263,700260,10043,80033,60032,0009,40042,10039,70035,9006,4008,8009,0008,5007,9007,8008,1005,9007,3006,900302,5002,40070034,300254,800269,900119,60023,90017,90017,20016,20017,20015,0009,7009,10010,80010,1007,7006,1007,3005,6005,4005,30029,90032,50032,40041,445000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
346,200
350,500
414,300
23,900
119,400
269,900
254,800
34,300
500
2,400
302,500
6,900
3,300
0
0
0
3,500
0
0
0
29,500
0
0
0
4,800
0
0
0
226,800
0
0
00226,8000004,80000029,5000003,5000003,3006,900302,5002,40050034,300254,800269,900119,40023,900414,300350,500346,2000000000000000000000000000000000
       Accounts payable 
0
0
0
40,583
38,100
41,600
46,900
42,779
33,900
39,700
42,500
34,678
39,600
48,200
41,400
47,373
39,500
50,900
46,900
51,400
44,800
58,000
52,200
55,500
54,300
55,000
56,200
53,100
51,800
57,800
47,500
62,800
43,500
56,000
49,400
65,000
41,600
72,300
45,400
73,400
50,600
63,300
40,100
52,200
54,700
49,000
37,700
42,000
49,300
43,800
31,500
38,800
38,700
42,200
30,200
51,100
44,700
54,500
53,300
78,100
77,200
69,400
69,40077,20078,10053,30054,50044,70051,10030,20042,20038,70038,80031,50043,80049,30042,00037,70049,00054,70052,20040,10063,30050,60073,40045,40072,30041,60065,00049,40056,00043,50062,80047,50057,80051,80053,10056,20055,00054,30055,50052,20058,00044,80051,40046,90050,90039,50047,37341,40048,20039,60034,67842,50039,70033,90042,77946,90041,60038,10040,583000
       Other Current Liabilities 
0
0
0
108,194
81,600
80,600
73,800
88,569
106,400
113,300
120,200
113,057
120,100
104,900
100,000
27,233
29,200
30,500
30,800
26,200
33,300
38,300
44,200
32,700
40,200
41,400
37,900
31,800
34,900
34,000
36,000
27,900
26,900
30,000
32,900
27,000
28,600
27,700
25,000
5,100
25,700
28,900
30,400
7,700
33,100
34,700
65,600
5,900
71,800
67,300
72,300
4,300
76,200
39,500
37,100
69,500
52,600
34,500
49,900
46,900
48,100
34,800
34,80048,10046,90049,90034,50052,60069,50037,10039,50076,2004,30072,30067,30071,8005,90065,60034,70033,1007,70030,40028,90025,7005,10025,00027,70028,60027,00032,90030,00026,90027,90036,00034,00034,90031,80037,90041,40040,20032,70044,20038,30033,30026,20030,80030,50029,20027,233100,000104,900120,100113,057120,200113,300106,40088,56973,80080,60081,600108,194000
   > Long-term Liabilities 
0
0
0
214,815
219,500
225,400
219,100
193,383
189,000
219,900
219,400
188,359
181,700
181,200
174,000
148,037
147,400
144,800
142,700
301,500
315,800
315,100
315,600
423,500
436,800
437,200
435,100
424,600
433,000
429,600
427,200
426,100
434,800
492,500
485,700
379,500
292,100
454,500
411,100
421,500
442,900
146,400
498,200
516,500
518,300
572,100
574,700
584,100
586,000
612,300
619,400
617,400
619,800
621,000
625,900
701,700
709,600
717,800
742,400
560,100
527,700
538,700
538,700527,700560,100742,400717,800709,600701,700625,900621,000619,800617,400619,400612,300586,000584,100574,700572,100518,300516,500498,200146,400442,900421,500411,100454,500292,100379,500485,700492,500434,800426,100427,200429,600433,000424,600435,100437,200436,800423,500315,600315,100315,800301,500142,700144,800147,400148,037174,000181,200181,700188,359219,400219,900189,000193,383219,100225,400219,500214,815000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
96,100
101,500
96,100
97,200
92,700
90,700
93,800
92,300
92,800
92,600
94,100
94,400
113,600
112,400
112,900
114,100
121,600
122,300
122,700
123,100
121,000
121,700
120,900
625,900
0
0
89,300
0
0
0
0
000089,30000625,900120,900121,700121,000123,100122,700122,300121,600114,100112,900112,400113,60094,40094,10092,60092,80092,30093,80090,70092,70097,20096,100101,50096,1000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
100
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000001000000000000000000000000000000000
> Total Stockholder Equity
0
0
0
264,761
292,000
302,200
293,700
301,564
301,700
302,100
339,700
346,572
348,000
353,800
357,300
369,324
378,500
452,700
456,200
460,600
465,600
468,000
486,700
480,100
502,800
483,900
398,100
412,200
409,900
416,600
406,900
360,500
335,700
339,300
331,200
347,600
339,900
498,800
505,100
495,000
493,900
496,200
491,700
476,900
466,200
459,300
444,200
441,600
427,700
422,400
412,200
380,400
375,100
358,700
343,800
371,100
351,100
373,500
459,900
498,900
527,900
535,900
535,900527,900498,900459,900373,500351,100371,100343,800358,700375,100380,400412,200422,400427,700441,600444,200459,300466,200476,900491,700496,200493,900495,000505,100498,800339,900347,600331,200339,300335,700360,500406,900416,600409,900412,200398,100483,900502,800480,100486,700468,000465,600460,600456,200452,700378,500369,324357,300353,800348,000346,572339,700302,100301,700301,564293,700302,200292,000264,761000
   Common Stock
0
0
0
30,025
30,000
30,000
30,000
30,025
30,000
30,000
30,000
30,025
30,000
30,000
30,000
30,025
30,000
33,800
33,800
33,800
33,800
33,800
33,800
33,800
33,800
33,800
33,800
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60033,80033,80033,80033,80033,80033,80033,80033,80033,80033,80030,00030,02530,00030,00030,00030,02530,00030,00030,00030,02530,00030,00030,00030,025000
   Retained Earnings Total Equity00000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
-157,410
0
0
0
-163,520
0
0
0
-184,904
0
0
0
-182,874
10,100
8,400
5,800
-400
-400
1,100
14,300
19,400
40,700
33,700
33,700
37,000
0
254,700
219,800
37,600
0
34,200
0
29,900
0
-4,000
0
-4,200
0
-4,200
0
-3,900
0
-4,000
0
259,400
0
-3,000
0
-2,000
0
-35,700
0
-2,000
0
-10,400
0
1,100
0
-10,900
-10,90001,1000-10,4000-2,0000-35,7000-2,0000-3,0000259,4000-4,0000-3,9000-4,2000-4,2000-4,000029,900034,200037,600219,800254,700037,00033,70033,70040,70019,40014,3001,100-400-4005,8008,40010,100-182,874000-184,904000-163,520000-157,410000
   Capital Surplus 00000000000000000000000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
209,063
262,000
243,700
234,700
234,592
266,800
260,300
271,000
270,194
314,200
313,900
311,700
305,891
143,200
217,200
219,800
209,100
225,600
224,500
211,300
189,300
184,900
191,900
191,900
163,000
219,800
-34,900
149,200
182,200
219,800
185,600
219,800
170,100
219,800
219,800
219,800
204,200
219,800
204,200
219,800
219,800
219,800
219,800
219,800
-39,600
219,800
219,800
219,800
219,800
219,800
219,800
219,800
219,800
219,800
219,800
219,800
219,800
219,800
219,800
219,800219,800219,800219,800219,800219,800219,800219,800219,800219,800219,800219,800219,800219,800-39,600219,800219,800219,800219,800219,800204,200219,800204,200219,800219,800219,800170,100219,800185,600219,800182,200149,200-34,900219,800163,000191,900191,900184,900189,300211,300224,500225,600209,100219,800217,200143,200305,891311,700313,900314,200270,194271,000260,300266,800234,592234,700243,700262,000209,063000



6.4. Balance Sheets

Currency in EUR. All numbers in thousands.